BALCHEM CORP (BCPC) Form 8-K — Oct 23, 2026
Balchem Corporation (NASDAQ: BCPC) reported record third-quarter 2026 results, with net sales of $290.7 million up 8.6% year-over-year and GAAP net earnings of $46.7 million up 16.0%. Adjusted EPS was $1.57 versus $1.35 a year ago, and adjusted EBITDA rose 12.4% to $80.3 million, with growth across all three segments — Human Nutrition & Health, Animal Nutrition & Health (segment earnings up 82.8%), and Specialty Products.
Key figures
- Eps
- 1.46
- Revenue
- 290700000
- Net Income
- 46700000
- Total Debt
- 124000000
- Revenue Yoy
- 8.6%
- Total Assets
- 1703572000
- Cash Position
- 66300000
- Net debt
- 57700000
- Q3 buybacks
- 28000000
- Ttm buybacks
- 127000000
- Leverage ratio
- 0.2x
- Gross margin pct
- 36.4%
- Nine month revenue
- 845364000
- Adjusted ebitda yoy
- 12.4%
- Adjusted eps q3 2025
- 1.35
- Adjusted eps q3 2026
- 1.57
- Free cash flow q3 2026
- 57900000
- Nine month diluted eps
- 4.09
- Adjusted ebitda q3 2026
- 80300000
- Human nutrition sales q3
- 188200000
- Animal nutrition sales q3
- 63000000
- Operating cash flow q3 2026
- 69800000
- Specialty products sales q3
- 37300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.